Background/Aim: Up-regulation of caveolin (CAV)-1 is associated with aggressive prostate
cancer. Recently, it has been inferred that CAV2, a co-factor sub-type of CAV1, cross-talks …

High MET expression in renal cell carcinoma (RCC) and MET activation in bone metastases
are reportedly important in progression of several cancers. To find new treatment targets in …

Resistance to or relapse after androgen deprivation therapy (ADT) remains a significant
problem in patients with prostate cancer. Several studies have hypothesized that the …

Hepatocyte growth factor (HGF) is a well-known multifunctional growth factor, and evidence
has accumulated indicating that the HGF/MET (HGF receptor) signaling axis is involved in …

Aim: Up-regulation of caveolin-1 (CAV1) is associated with aggressive prostate cancer. Among
Caucasian and African-American patients, plasma CAV1 levels are elevated in patients …

Aim: Dutasteride, a dual 5α-reductase inhibitor, is used to treat benign prostatic hyperplasia
(BPH). However, its histopathological effects on the morphometrics of blood vessels and …

Aim: To evaluate the relationship between the Caveolin-1 (CAV1) T29107A (rs7804372)
polymorphism and the risk of prostate cancer among Japanese populations, and the …

This study aims to evaluate the relationship between the cyclooxygenase 2 (COX2) G1195A
(rs689465) polymorphism and the risk of prostate cancer in a Japanese population and the …

MET, a c-met proto-oncogene product and hepatocyte growth factor (HGF) receptor, is known
to play an important role in cancer progression, including bone metastasis. In a previous …

In renal cell carcinoma patients with inferior vena cava (IVC) extension, the difficulty of
resection increases with the degree of venous extension, which in turn increases the risk of …